Where the money is: The top 100 venture investors in biotech
It’s no great surprise that RA Capital weighed in — again — as the most ubiquitous venture player in private biotech rounds through 2024. Or that ARCH participated in somewhat fewer, though overall larger, rounds. Run through ...
It’s no great surprise that RA Capital weighed in — again — as the most ubiquitous venture player in private biotech rounds through 2024. Or that ARCH participated in somewhat fewer, though overall larger, rounds.
Run through ...
